NCT00002320已完成3 期
A Randomized, Double-Blind Multicenter Trial to Compare the Safety and Efficacy of Lamivudine (3TC; GR109714X) Monotherapy Versus Zidovudine (AZT) Monotherapy Versus 3TC Administered With AZT in the Treatment of HIV-1 Infected Patients Who Are AZT Naive (< 4 Weeks) With CD4 Cell Counts of 200-500 Cells/mm3
Glaxo Wellcome40 个研究点 分布在 3 个国家目标入组 320 人开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 320
- 试验地点
- 40
研究概览
简要总结
To evaluate the safety and efficacy of high-dose lamivudine (3TC) alone versus zidovudine (AZT) alone versus 3TC at high and low doses in combination with AZT in HIV-1 infected patients.
PER 02/27/95 AMENDMENT: To evaluate the efficacy and safety of both blinded and open-label combination therapy.
详细描述
Patients are randomized to one of four treatment arms: 3TC alone, AZT alone, low-dose 3TC plus AZT, or high-dose 3TC plus AZT. Patients receive treatment for 32 weeks, with possible extension to 52 weeks.
PER 02/27/95 AMENDMENT: Patients may continue therapy on AZT and low-dose 3TC on an open-label basis. Open-label therapy continues with follow-up every 8 weeks until intolerable toxicity occurs or study terminates.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have:
- •HIV positivity.
- •CD4 count 200-500 cells/mm
- •AZT naive status (<= 4 weeks of prior AZT).
排除标准
- •Patients with the following prior condition are excluded:
- •History of intolerance to AZT.
- •Prior Medication:
- •More than 4 weeks of prior AZT.
- •Any prior antiretroviral treatment other than AZT.
研究者
研究点 (40)
Loading locations...
相似试验
已完成
2 期
A Comparison of Zidovudine Plus Lamivudine Versus ddI Used Alone or in Combination With Zidovudine in HIV-1 Infected ChildrenHIV InfectionsNCT00001066National Institute of Allergy and Infectious Diseases (NIAID)740
已完成
不适用
Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected PatientsHIV InfectionsNCT00006617National Institute of Allergy and Infectious Diseases (NIAID)25
已完成
2 期
Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or DidanosineHIV InfectionsNCT00000838National Institute of Allergy and Infectious Diseases (NIAID)256
已完成
2 期
A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3HIV InfectionsNCT00000712National Institute of Allergy and Infectious Diseases (NIAID)400
已完成
4 期
Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy SubjectsDyslipidemiasGlucose Metabolism DisordersMetabolic DiseasesLipodystrophyCardiovascular DiseaseHIV InfectionsNCT00192621Kirby Institute50